SNX32
gene geneOn this page
Also known as FLJ30934
Summary
SNX32 (sorting nexin 32, HGNC:26423) is a protein-coding gene on chromosome 11q13.1, encoding Sorting nexin-32 (Q86XE0). Involved in endosomal trafficking of cargo proteins, including transferrin-bound transferrin receptor (TFRC), cation-independent mannose-6-phosphate receptor (IGF2R) and epidermal growth factor receptor (EGFR).
Predicted to enable phosphatidylinositol binding activity. Predicted to be involved in retrograde transport, endosome to Golgi. Predicted to be located in cytoplasmic vesicle and cytosol. Predicted to be active in endosome.
Source: NCBI Gene 254122 — RefSeq curated summary.
At a glance
- GWAS associations: 12
- Clinical variants (ClinVar): 58 total
- MANE Select transcript:
NM_152760
Identifiers
Gene identifiers
| Field | Value |
|---|---|
| HGNC ID | HGNC:26423 |
| Approved symbol | SNX32 |
| Name | sorting nexin 32 |
| Location | 11q13.1 |
| Locus type | gene with protein product |
| Status | Approved |
| Aliases | FLJ30934 |
| Ensembl gene | ENSG00000172803 |
| Ensembl biotype | protein_coding |
| OMIM | 621073 |
| Entrez | 254122 |
Gene structure
Transcript identifiers
Ensembl transcripts: 12 — 7 retained_intron, 4 protein_coding, 1 protein_coding_CDS_not_defined
ENST00000308342, ENST00000524729, ENST00000526972, ENST00000530101, ENST00000531503, ENST00000531795, ENST00000533236, ENST00000533298, ENST00000534387, ENST00000913492, ENST00000946609, ENST00000946610
RefSeq mRNA: 1 — MANE Select: NM_152760
NM_152760
CCDS: CCDS8113
Canonical transcript exons
ENST00000308342 — 13 exons
| Exon | Start | End |
|---|---|---|
| ENSE00001235659 | 65851328 | 65851403 |
| ENSE00001235739 | 65853282 | 65853701 |
| ENSE00002170734 | 65833963 | 65834101 |
| ENSE00002501828 | 65851640 | 65851679 |
| ENSE00003494926 | 65850150 | 65850271 |
| ENSE00003513049 | 65850751 | 65850855 |
| ENSE00003530657 | 65849478 | 65849582 |
| ENSE00003575550 | 65850431 | 65850554 |
| ENSE00003587068 | 65849920 | 65850030 |
| ENSE00003612000 | 65852630 | 65852789 |
| ENSE00003649426 | 65852465 | 65852551 |
| ENSE00003657800 | 65851055 | 65851160 |
| ENSE00003674961 | 65852873 | 65852958 |
Expression profiles
Bgee: expression breadth ubiquitous, 163 present calls, max score 93.56.
FANTOM5 (CAGE): breadth broad, TPM avg 1.9727 / max 143.5361, expressed in 609 samples.
FANTOM5 promoters (2 alternative TSS)
| Promoter ID | TPM avg | Samples expressed |
|---|---|---|
| 115214 | 1.4526 | 524 |
| 115215 | 0.5201 | 193 |
Top tissues by expression
244 total, by Bgee expression score (0-100, higher = more expressed):
| Tissue | Anatomy ID | Expression score | Quality |
|---|---|---|---|
| right frontal lobe | UBERON:0002810 | 93.56 | gold quality |
| Brodmann (1909) area 9 | UBERON:0013540 | 91.58 | gold quality |
| nucleus accumbens | UBERON:0001882 | 90.99 | gold quality |
| caudate nucleus | UBERON:0001873 | 90.31 | gold quality |
| anterior cingulate cortex | UBERON:0009835 | 90.30 | gold quality |
| putamen | UBERON:0001874 | 89.52 | gold quality |
| dorsolateral prefrontal cortex | UBERON:0009834 | 88.64 | gold quality |
| prefrontal cortex | UBERON:0000451 | 87.20 | gold quality |
| cortical plate | UBERON:0005343 | 86.77 | gold quality |
| amygdala | UBERON:0001876 | 86.63 | gold quality |
| neocortex | UBERON:0001950 | 86.50 | gold quality |
| frontal cortex | UBERON:0001870 | 86.11 | gold quality |
| right hemisphere of cerebellum | UBERON:0014890 | 86.01 | gold quality |
| cerebellar hemisphere | UBERON:0002245 | 84.71 | gold quality |
| cerebral cortex | UBERON:0000956 | 84.51 | gold quality |
| cerebellar cortex | UBERON:0002129 | 84.49 | gold quality |
| cerebellum | UBERON:0002037 | 82.83 | gold quality |
| hypothalamus | UBERON:0001898 | 82.55 | gold quality |
| forebrain | UBERON:0001890 | 82.47 | gold quality |
| primary visual cortex | UBERON:0002436 | 82.06 | gold quality |
| brain | UBERON:0000955 | 81.72 | gold quality |
| Ammon’s horn | UBERON:0001954 | 81.41 | gold quality |
| temporal lobe | UBERON:0001871 | 79.47 | gold quality |
| male germ line stem cell (sensu Vertebrata) in testis | CL:0000089 ∩ UBERON:0000473 | 77.79 | gold quality |
| sperm | CL:0000019 | 77.71 | silver quality |
| occipital lobe | UBERON:0002021 | 76.55 | gold quality |
| C1 segment of cervical spinal cord | UBERON:0006469 | 76.40 | gold quality |
| ganglionic eminence | UBERON:0004023 | 75.15 | gold quality |
| superior frontal gyrus | UBERON:0002661 | 74.92 | gold quality |
| substantia nigra | UBERON:0002038 | 74.57 | gold quality |
Single-cell (SCXA)
Detected in 4 experiment(s), a significant marker in 3.
| Experiment | Marker? | Max mean expression |
|---|---|---|
| E-CURD-112 | yes | 15172.68 |
| E-MTAB-9543 | yes | 3567.33 |
| E-ANND-3 | yes | 18.96 |
| E-MTAB-8060 | no | 81.20 |
Regulation
Is transcription factor: no
Upstream regulators (CollecTRI, top): NR1I2
miRNA regulators (miRDB)
25 targeting SNX32, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):
| miRNA | Max score | Avg score | miRNA target_count |
|---|---|---|---|
| HSA-MIR-4455 | 100.00 | 65.48 | 1587 |
| HSA-MIR-4747-5P | 100.00 | 67.90 | 2681 |
| HSA-MIR-5196-5P | 100.00 | 67.98 | 2761 |
| HSA-MIR-6783-3P | 99.89 | 67.92 | 2059 |
| HSA-MIR-1343-3P | 99.89 | 66.78 | 1815 |
| HSA-MIR-3151-5P | 99.86 | 63.83 | 1069 |
| HSA-MIR-4447 | 99.85 | 67.81 | 2900 |
| HSA-MIR-4319 | 99.76 | 69.83 | 2586 |
| HSA-MIR-187-5P | 99.74 | 70.26 | 1404 |
| HSA-MIR-670-5P | 99.67 | 69.94 | 1565 |
| HSA-MIR-486-3P | 99.51 | 66.82 | 1901 |
| HSA-MIR-125A-5P | 99.36 | 70.59 | 1640 |
| HSA-MIR-125B-5P | 99.36 | 70.36 | 1662 |
| HSA-MIR-145-3P | 99.33 | 67.66 | 764 |
| HSA-MIR-6852-5P | 99.17 | 66.69 | 2073 |
| HSA-MIR-876-3P | 98.76 | 68.23 | 945 |
| HSA-MIR-323A-5P | 98.59 | 65.13 | 651 |
| HSA-MIR-6804-5P | 98.39 | 65.77 | 1084 |
| HSA-MIR-1262 | 98.17 | 66.52 | 757 |
| HSA-MIR-3127-5P | 97.52 | 65.24 | 786 |
| HSA-MIR-3918 | 96.13 | 64.65 | 1300 |
| HSA-MIR-4435 | 95.90 | 65.47 | 1201 |
| HSA-MIR-4683 | 95.29 | 65.98 | 631 |
| HSA-MIR-6732-5P | 93.97 | 64.65 | 422 |
| HSA-MIR-450A-5P | 93.89 | 64.57 | 50 |
Literature-anchored findings (GeneRIF, showing 1)
- SNX32 Regulates Sorting and Trafficking of Activated EGFR to the Lysosomal Degradation Pathway. (PMID:39073202)
Cross-species orthologs
9 orthologs
| Organism | Symbol | Gene ID |
|---|---|---|
| danio_rerio | si:dkey-28n18.9 | ENSDARG00000097193 |
| mus_musculus | Snx32 | ENSMUSG00000056185 |
| rattus_norvegicus | Snx32 | ENSRNOG00000026527 |
| drosophila_melanogaster | Snx1 | FBGN0031534 |
| drosophila_melanogaster | Snx6 | FBGN0032005 |
| drosophila_melanogaster | SH3PX1 | FBGN0040475 |
| caenorhabditis_elegans | WBGENE00003086 | |
| caenorhabditis_elegans | WBGENE00004927 | |
| caenorhabditis_elegans | WBGENE00013354 |
Paralogs (15): SNX11 (ENSG00000002919), SNX1 (ENSG00000028528), SNX10 (ENSG00000086300), SNX5 (ENSG00000089006), SNX8 (ENSG00000106266), SNX3 (ENSG00000112335), SNX4 (ENSG00000114520), SNX6 (ENSG00000129515), SNX9 (ENSG00000130340), SNX12 (ENSG00000147164), SNX30 (ENSG00000148158), SNX7 (ENSG00000162627), SNX33 (ENSG00000173548), SNX18 (ENSG00000178996), SNX2 (ENSG00000205302)
Protein
Protein identifiers
Sorting nexin-32 — Q86XE0 (reviewed: Q86XE0)
Alternative names: Sorting nexin-6B
All UniProt accessions (1): Q86XE0
UniProt curated annotations — full annotation on UniProt →
Function. Involved in endosomal trafficking of cargo proteins, including transferrin-bound transferrin receptor (TFRC), cation-independent mannose-6-phosphate receptor (IGF2R) and epidermal growth factor receptor (EGFR). Functions redundantly with other BAR domain-containing sorting nexins in endosome to trans-Golgi network transport of IGF2R. Regulates in coordination with SNX5 sorting and trafficking of EGF-activated EGFR to multivesicular bodies for lysosomal degradation. Plays an essential role in neurite outgrowth, controlling basigin/EMMPRIN (BSG) trafficking to the cell surface.
Subunit / interactions. Interacts with BAR domain-containing sorting nexins SNX1, SNX2, SNX4, SNX5 and SNX6. Interacts (via PX domain) with cargo proteins transferrin-bound TFRC, IGF2R and BSG; the interaction regulates their intracellular trafficking. Interacts with EGFR; the interaction is required for endolysosomal EGFR trafficking.
Subcellular location. Cell membrane. Early endosome. Golgi apparatus. trans-Golgi network. Recycling endosome. Late endosome.
Similarity. Belongs to the sorting nexin family.
Isoforms (2)
| UniProt ID | Names | Canonical? |
|---|---|---|
| Q86XE0-1 | 1 | yes |
| Q86XE0-2 | 2 |
RefSeq proteins (1): NP_689973* (*=MANE)
Domains & families (InterPro)
| ID | Name | Type |
|---|---|---|
| IPR001683 | PX_dom | Domain |
| IPR014637 | SNX5/SNX6/SNX32 | Family |
| IPR015404 | Vps5_C | Domain |
| IPR027267 | AH/BAR_dom_sf | Homologous_superfamily |
| IPR036871 | PX_dom_sf | Homologous_superfamily |
Pfam: PF00787, PF09325
UniProt features (20 total): helix 6, strand 3, sequence variant 3, splice variant 2, mutagenesis site 2, chain 1, domain 1, sequence conflict 1, coiled-coil region 1
Structure
Experimental structures (PDB)
1 structures.
| PDB | Method | Resolution (Å) |
|---|---|---|
| 6E8R | X-RAY DIFFRACTION | 2.27 |
Predicted structure (AlphaFold)
| Model | pLDDT | Fraction very-high |
|---|---|---|
| AF-Q86XE0-F1 | 89.43 | 0.72 |
Functional residue map
Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.
Mutagenesis-validated functional residues (2):
| Position | Phenotype |
|---|---|
| 131 | loss of interaction with tfrc, igf2r and bsg. does not affect interaction with snx1. |
| 256 | decreased interaction with snx5. |
Function
Pathways and Gene Ontology
Reactome pathways
0 pathways
MSigDB gene sets: 95 (showing top):
GOBP_REGULATION_OF_AUTOPHAGY, GOBP_LYSOSOMAL_TRANSPORT, GOBP_ENDOSOME_ORGANIZATION, GOBP_NEURON_PROJECTION_EXTENSION, GOBP_VESICLE_ORGANIZATION, STARK_PREFRONTAL_CORTEX_22Q11_DELETION_DN, GOBP_ENDOSOME_TO_LYSOSOME_TRANSPORT, GOBP_GROWTH, GOBP_VACUOLAR_TRANSPORT, GOBP_NEUROGENESIS, GOBP_VESICLE_MEDIATED_TRANSPORT, chr11q13, GOBP_MACROAUTOPHAGY, GOCC_TRANS_GOLGI_NETWORK, GOBP_REGULATION_OF_CATABOLIC_PROCESS
GO Biological Process (6): protein transport (GO:0015031), endosomal transport (GO:0016197), regulation of macroautophagy (GO:0016241), endosome to lysosome transport via multivesicular body sorting pathway (GO:0032510), retrograde transport, endosome to Golgi (GO:0042147), neuron projection extension (GO:1990138)
GO Molecular Function (3): dynactin binding (GO:0034452), phosphatidylinositol binding (GO:0035091), protein binding (GO:0005515)
GO Cellular Component (10): endosome (GO:0005768), early endosome (GO:0005769), late endosome (GO:0005770), trans-Golgi network (GO:0005802), cytosol (GO:0005829), plasma membrane (GO:0005886), retromer complex (GO:0030904), early endosome membrane (GO:0031901), recycling endosome (GO:0055037), tubular endosome (GO:0097422)
GO top-level categories
Rollup of top GO terms by namespace:
| Category | Terms |
|---|---|
| endosome | 4 |
| endomembrane system | 2 |
| cellular anatomical structure | 2 |
| transport | 1 |
| intracellular protein localization | 1 |
| establishment of protein localization | 1 |
| vesicle-mediated transport | 1 |
| intracellular transport | 1 |
| regulation of autophagy | 1 |
| macroautophagy | 1 |
| endosome to lysosome transport | 1 |
| endosome transport via multivesicular body sorting pathway | 1 |
| intercellular transport | 1 |
| endosomal transport | 1 |
| cytosolic transport | 1 |
| developmental cell growth | 1 |
| neuron projection morphogenesis | 1 |
| developmental growth involved in morphogenesis | 1 |
| cytoskeletal protein binding | 1 |
| anion binding | 1 |
| binding | 1 |
| cytoplasmic vesicle | 1 |
| Golgi apparatus subcompartment | 1 |
| cytoplasm | 1 |
| membrane | 1 |
| cell periphery | 1 |
| membrane protein complex | 1 |
| early endosome | 1 |
| endosome membrane | 1 |
Protein interactions and networks
STRING
660 interactions, top by confidence (×1000):
| Protein A | Protein B | Partner UniProt | Score |
|---|---|---|---|
| SNX32 | SNX2 | P82862 | 980 |
| SNX32 | SNX1 | Q13596 | 965 |
| SNX32 | SNX5 | Q9Y5X3 | 800 |
| SNX32 | SNX6 | Q9UNH7 | 712 |
| SNX32 | SNX7 | Q9UNH6 | 668 |
| SNX32 | VPS29 | Q9UBQ0 | 658 |
| SNX32 | SNX8 | Q9Y5X2 | 643 |
| SNX32 | SNX33 | Q8WV41 | 637 |
| SNX32 | VPS26A | O75436 | 633 |
| SNX32 | SNX27 | Q96L92 | 620 |
| SNX32 | VPS35 | Q96QK1 | 599 |
| SNX32 | VPS26B | Q4G0F5 | 598 |
| SNX32 | SNX3 | O60493 | 584 |
| SNX32 | SNX18 | Q96RF0 | 571 |
| SNX32 | SNX4 | O95219 | 568 |
IntAct
44 interactions, top by confidence:
| A | B | Type | Score |
|---|---|---|---|
| SNX1 | SNX32 | psi-mi:“MI:0915”(physical association) | 0.870 |
| SNX32 | SNX2 | psi-mi:“MI:0914”(association) | 0.740 |
| SNX2 | SNX32 | psi-mi:“MI:0915”(physical association) | 0.740 |
| SNX1 | SNX2 | psi-mi:“MI:0914”(association) | 0.740 |
| SNX32 | TFIP11 | psi-mi:“MI:0915”(physical association) | 0.560 |
| SNX32 | NME7 | psi-mi:“MI:0915”(physical association) | 0.560 |
| SNX32 | SPANXB1 | psi-mi:“MI:0915”(physical association) | 0.560 |
| GRXCR1 | SNX32 | psi-mi:“MI:0915”(physical association) | 0.560 |
| EML2 | SNX32 | psi-mi:“MI:0915”(physical association) | 0.560 |
| SNX32 | MNS1 | psi-mi:“MI:0915”(physical association) | 0.560 |
| C22orf39 | SNX32 | psi-mi:“MI:0915”(physical association) | 0.560 |
| incE | SNX2 | psi-mi:“MI:0914”(association) | 0.430 |
| SNX30 | SNX32 | psi-mi:“MI:0915”(physical association) | 0.400 |
| M | psi-mi:“MI:0914”(association) | 0.350 | |
| SNX32 | CHMP2A | psi-mi:“MI:0914”(association) | 0.350 |
| SNX32 | SNX2 | psi-mi:“MI:0915”(physical association) | 0.000 |
| SNX32 | SNX1 | psi-mi:“MI:0915”(physical association) | 0.000 |
| SNX32 | TFIP11 | psi-mi:“MI:0915”(physical association) | 0.000 |
| SNX1 | SNX32 | psi-mi:“MI:0915”(physical association) | 0.000 |
| NME7 | SNX32 | psi-mi:“MI:0915”(physical association) | 0.000 |
BioGRID (38): SNX32 (Two-hybrid), SNX1 (Two-hybrid), SNX1 (Affinity Capture-MS), SNX6 (Affinity Capture-MS), RAD51 (Affinity Capture-MS), IFFO1 (Affinity Capture-MS), SNX2 (Affinity Capture-MS), CEP44 (Affinity Capture-MS), RNF40 (Affinity Capture-MS), BRCA2 (Affinity Capture-MS), PIK3R1 (Affinity Capture-MS), TEX11 (Two-hybrid), TSG101 (Two-hybrid), SNX32 (Two-hybrid), SNX32 (Two-hybrid)
ESM2 similar proteins: A0A1B7YDZ4, B1H267, I1RXT2, O14243, O60107, O74960, O94447, P0CR58, P0CR59, P0CR62, P0CR63, P0CR64, P0CR65, P32912, P32913, P40531, P40959, P47057, Q09746, Q10253, Q28GP7, Q3ZBM5, Q4PHC3, Q4VAA7, Q4WQI6, Q522W5, Q5B797, Q5R613, Q6C238, Q6C9X0, Q6CGJ5, Q6CHY6, Q6CTQ0, Q6CUC4, Q6FPT9, Q6NRL2, Q6P8X1, Q759T1, Q75B65, Q75C43
Diamond homologs: B1H267, Q3ZBM5, Q4V7P7, Q5R613, Q6P8X1, Q80ZJ7, Q86XE0, Q9D8U8, Q9UNH7, Q9Y5X3, B9DFS6
SIGNOR signaling
0 interactions.
Disease & clinical
Clinical variants and AI predictions
ClinVar
58 variants total. Per-class counts are floors (≥ shown; pagination cap):
| Classification | Count (floor) |
|---|---|
| Pathogenic | 0 |
| Likely pathogenic | 0 |
| Uncertain significance | 51 |
| Likely benign | 1 |
| Benign | 0 |
Top pathogenic / likely-pathogenic (0)
SpliceAI
2581 predictions. Top by Δscore:
| Variant | Effect | Δscore |
|---|---|---|
| 11:65850010:GAGGA:G | donor_gain | 1.0000 |
| 11:65850012:G:GT | donor_gain | 1.0000 |
| 11:65850012:GGA:G | donor_gain | 1.0000 |
| 11:65850013:G:GT | donor_gain | 1.0000 |
| 11:65850013:GA:G | donor_gain | 1.0000 |
| 11:65850015:G:GG | donor_gain | 1.0000 |
| 11:65850031:G:GG | donor_gain | 1.0000 |
| 11:65850036:G:GT | donor_gain | 1.0000 |
| 11:65850270:GC:G | donor_gain | 1.0000 |
| 11:65850272:G:GG | donor_gain | 1.0000 |
| 11:65850430:GGGA:G | acceptor_gain | 1.0000 |
| 11:65850551:GGAT:G | donor_gain | 1.0000 |
| 11:65850552:G:GT | donor_gain | 1.0000 |
| 11:65850560:C:G | donor_gain | 1.0000 |
| 11:65850741:T:TA | acceptor_gain | 1.0000 |
| 11:65850750:GCT:G | acceptor_gain | 1.0000 |
| 11:65851159:GT:G | donor_gain | 1.0000 |
| 11:65851161:G:GG | donor_gain | 1.0000 |
| 11:65851396:C:G | donor_gain | 1.0000 |
| 11:65851404:G:GG | donor_gain | 1.0000 |
| 11:65852443:A:AG | acceptor_gain | 1.0000 |
| 11:65852444:G:GG | acceptor_gain | 1.0000 |
| 11:65852624:TCCTA:T | acceptor_loss | 1.0000 |
| 11:65852625:CCTAG:C | acceptor_loss | 1.0000 |
| 11:65852626:CTAG:C | acceptor_loss | 1.0000 |
| 11:65852627:TAGG:T | acceptor_loss | 1.0000 |
| 11:65852628:A:AG | acceptor_gain | 1.0000 |
| 11:65852628:A:T | acceptor_loss | 1.0000 |
| 11:65852629:G:GG | acceptor_gain | 1.0000 |
| 11:65852629:G:T | acceptor_loss | 1.0000 |
AlphaMissense
2630 scored. Top likely-pathogenic:
| Variant | Protein change | am_pathogenicity |
|---|---|---|
| 11:65849565:T:C | F42L | 1.000 |
| 11:65849567:C:A | F42L | 1.000 |
| 11:65849567:C:G | F42L | 1.000 |
| 11:65849572:T:A | V44D | 1.000 |
| 11:65850447:T:C | F131L | 1.000 |
| 11:65850449:T:A | F131L | 1.000 |
| 11:65850449:T:G | F131L | 1.000 |
| 11:65849566:T:C | F42S | 0.999 |
| 11:65849977:T:C | F67L | 0.999 |
| 11:65849978:T:C | F67S | 0.999 |
| 11:65849979:C:A | F67L | 0.999 |
| 11:65849979:C:G | F67L | 0.999 |
| 11:65849987:T:C | L70P | 0.999 |
| 11:65850163:C:A | P89H | 0.999 |
| 11:65850177:T:C | F94L | 0.999 |
| 11:65850179:T:A | F94L | 0.999 |
| 11:65850179:T:G | F94L | 0.999 |
| 11:65850257:G:C | K120N | 0.999 |
| 11:65850257:G:T | K120N | 0.999 |
| 11:65850435:T:C | Y127H | 0.999 |
| 11:65850436:A:G | Y127C | 0.999 |
| 11:65850439:T:C | L128P | 0.999 |
| 11:65850448:T:C | F131S | 0.999 |
| 11:65850452:G:C | K132N | 0.999 |
| 11:65850452:G:T | K132N | 0.999 |
| 11:65850460:T:A | V135D | 0.999 |
| 11:65850534:T:C | F160L | 0.999 |
| 11:65850536:T:A | F160L | 0.999 |
| 11:65850536:T:G | F160L | 0.999 |
| 11:65852499:T:C | L287P | 0.999 |
dbSNP variants (sampled 300 via entrez): RS1000042091 (11:65850810 G>A,C), RS1000181791 (11:65834582 T>G), RS1000239290 (11:65839629 C>G), RS1000311415 (11:65839329 A>C), RS1000519348 (11:65833146 G>A,T), RS1000585621 (11:65840103 C>T), RS1000594143 (11:65834189 CTGTG>C,CTG,CTGTGTG,CTGTGTGTG), RS1000645432 (11:65840750 G>A), RS1000660508 (11:65832718 C>T), RS1000823349 (11:65833454 G>A), RS1000918035 (11:65834382 T>G), RS1000956254 (11:65840402 G>A,T), RS1001019694 (11:65848003 G>A), RS1001046107 (11:65847530 C>T), RS1001194170 (11:65839666 AT>A)
Disease associations
OMIM: gene MIM:621073 | disease phenotypes:
GenCC curated gene-disease
Mondo (0):
Orphanet (0):
HPO phenotypes
0 total (0 of 0 shown, HPO-id order):
GWAS associations
12 associations (top):
| Study | Trait | p-value |
|---|---|---|
| GCST001725_13 | Inflammatory bowel disease | 3.000000e-10 |
| GCST001937_15 | Breast cancer | 9.000000e-12 |
| GCST002481_8 | Acne (severe) | 3.000000e-11 |
| GCST005790_23 | Rosacea symptom severity | 1.000000e-08 |
| GCST006408_13 | Allergic sensitization | 3.000000e-07 |
| GCST008362_125 | Birth weight | 2.000000e-08 |
| GCST90002398_198 | Neutrophil count | 4.000000e-12 |
| GCST90002402_353 | Platelet count | 2.000000e-10 |
| GCST90002407_330 | White blood cell count | 7.000000e-18 |
| GCST90020025_1881 | Waist-to-hip ratio adjusted for BMI | 7.000000e-12 |
| GCST90020027_1497 | Waist-hip index | 4.000000e-12 |
| GCST90020029_331 | Waist circumference adjusted for body mass index | 2.000000e-11 |
EFO canonical traits (7, from GWAS)
| EFO ID | Trait name |
|---|---|
| EFO:0009180 | rosacea severity measurement |
| EFO:0005298 | allergic sensitization measurement |
| EFO:0004344 | birth weight |
| EFO:0004833 | neutrophil count |
| EFO:0004309 | platelet count |
| EFO:0007788 | BMI-adjusted waist-hip ratio |
| EFO:0007789 | BMI-adjusted waist circumference |
Drugs & pharmacology
Drug and pharmacology data
Is drug target: no
PharmGKB: 1 entry (VIP=true, CPIC=false)
CTD chemical–gene interactions
10 total (human), top 10 by PubMed support.
| Chemical | Actions (top 5) | PubMed papers |
|---|---|---|
| bisphenol S | decreases expression, decreases methylation | 2 |
| aristolochic acid I | increases expression | 1 |
| GSK-J4 | decreases expression | 1 |
| triphenyl phosphate | affects expression | 1 |
| bisphenol A | decreases expression | 1 |
| sodium arsenite | decreases expression | 1 |
| Acetaminophen | decreases expression | 1 |
| Arsenic | affects methylation | 1 |
| Benzo(a)pyrene | increases methylation | 1 |
| Cadmium Chloride | decreases expression | 1 |
Clinical trials (associated diseases)
0 trials via MONDO — disease-level, not drug-specific.
Related Atlas pages
No linked Atlas pages yet — the cross-entity mesh grows as the corpus expands.